Avanzanite Bioscience
Amsterdam
About Avanzanite Bioscience
Avanzanite Bioscience focuses on enhancing access to medicines for rare diseases in Europe. It operates as a commercial-stage enterprise, partnering with pharmaceutical companies like Advicenne and SIFI to facilitate the distribution and commercialization of orphan drugs. Avanzanite's collaborations extend across several European countries, including Ireland, Cyprus, Malta, Germany, and Austria, aiming to address the complexities and costs associated with the orphan drug market. The company's efforts are directed towards redefining the orphan drug landscape and unlocking new possibilities for patients suffering from rare diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $37.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2025)
- Website: avanzanite.com
- Phone: +31 020 301 2113
Industries & Categories
Advice, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/avanzanite-bioscience-58696 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.